Pieris Pharmaceuticals Inc.

At Pieris Pharmaceuticals Inc., we are committed to developing novel medicines to improve the clinical outcomes of patients suffering from cancer and respiratory diseases. Cinrebafusp alfa (PRS-343) is in clinical development and currently being evaluated as a treatment for gastric cancer.

We understand the interest of patients in accessing cinrebafusp alfa outside of clinical trials and prior to regulatory approval. However, participation in one of our clinical trials is currently the most appropriate way to access our investigational therapies. Pieris does not offer cinrebafusp alfa via expanded access at this time.

We recognize the need for Expanded Access programs, and we will re-evaluate the status of our policy based on data from ongoing and future clinical trials.

If you have additional questions, please consult your physician or to learn more about our clinical programs, including eligibility criteria and locations to visit www.clinicaltrials.gov.